Freestyle Libre Pro Flash Glucose Monitoring System
Abbott Diabetes Care, Inc. · Decision date Sep 1, 2026
What did the FDA decide?
The record for P150021/S061 describes a 30-day notice under reason code "Process Change - Manufacturer/Sterilizer/Packager/Supplier." The reported change is "addition of a secondary supplier and manufacturer for subcomponents and subassemblies for sensor kits." The filing identifies the sensor as a component of the FreeStyle Libre 14-day and FreeStyle Libre Pro Flash Glucose Monitoring Systems, so the stated scope concerns sensor-kit subcomponents and subassemblies rather than the complete systems.
The identifier links this notice to prior PMA P150021 as a supplement, not a new approval of any whole system. The decision code OK30 and date 2026-09-01 appear in the supplied record, but the text gives no details on which subcomponents or subassemblies, which supplier or manufacturer, or what evidence supported the change; it is a sponsor-stated purpose, not independent proof of safety or clinical effectiveness.
FDA approval order statement
addition of a secondary supplier and manufacturer for subcomponents and subassemblies for sensor kits. The sensor is a component of the FreeStyle Libre 14-day and FreeStyle Libre Pro Flash Glucose Monitoring Systems
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Clinical Chemistry
- Decision date
- Sep 1, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P150021/S061
- Regulatory pathway
- PMA supplement
- Applicant
- Abbott Diabetes Care, Inc.
- Product code
- MDS
- Decision code
- OK30
- Decision date
- Sep 1, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Sensor, glucose, invasive.
- Applicant
- Abbott Diabetes Care, Inc.
- Product code
- MDS
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P150021. Subsequent supplements may change the device or its indications.
FDA decision timeline
P150021 · Original PMA
FREESTYLE LIBRE PRO FLASH GLUCOSE MONITORING SYSTEM
P150021/S061 received
Application receipt date recorded by FDA.
P150021/S061 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P150021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Diabetes Care, Inc. | PMA approval | Sep 23, 2016 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Diabetes Care, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1360 S. Loop Rd., Alameda, CA, 94502
Sources and methodology
- Original FDA record: P150021/S061
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records